Wang Fangzheng^*†1, Jiang Chuner^‡1, Ye Zhiming^*†, Liu Tongxin^*†, Yan Fengqin^*†, Wang Lei^*†, Li Bin^*†, Hu Fujun^*†, Chen Ming^*†, Qin Weifeng^*†, Fu Zhenfu^*†

Oncology Research, Vol.26, No.2, pp. 277-287, 2018, DOI:10.3727/096504017X15079846743590

Abstract In this retrospective review of a single institution’s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III–IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more… More >

Hua Tao, Yiqin Zhou, Chengyun Yao, Dayong Gu, Wei Chen, Jincheng Lu

Oncology Research, Vol.25, No.8, pp. 1357-1362, 2017, DOI:10.3727/096504017X14889842609577

Abstract The aim of this study was to evaluate the efficacy and toxicity of intensity-modulated radiotherapy concurrent with weekly docetaxel in patients with node-positive esophageal squamous cell carcinoma after radical surgery. Between January 2011 and December 2013, a total of 46 eligible patients were enrolled. All patients received intensity-modulated radiotherapy concurrent with weekly docetaxel (20 mg/m² ). Patients were treated 5 days per week at 2.0 Gy/day. The total dose of external radiotherapy given was 50 Gy in 25 fractions. The primary endpoints included treatment completion and safety. The secondary endpoint was to assess whether the approach… More >